AC Immune SA has reported encouraging interim results from its phase 2 VacSYn clinical trial of ACI-7104.056, an anti-alpha-synuclein (a-syn) active immunotherapy for early Parkinson’s disease (PD).
Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection against infectious viruses, has vaccinated the first participant in its phase 2a clinical trial of OVX836. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback